Biotech News
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ir.arvinas.com2026-05-06 14:53 EST
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a